Table 1.
The characteristics of patients with glioma based on TCGA.
| Characteristic | Low expression of AKR1B1 | High expression of AKR1B1 | P |
|---|---|---|---|
| n | 348 | 348 | |
| WHO grade, n (%) | <0.001 | ||
| G2 | 160 (25.2%) | 64 (10.1%) | |
| G3 | 132 (20.8%) | 111 (17.5%) | |
| G4 | 17 (2.7%) | 151 (23.8%) | |
| IDH status, n (%) | <0.001 | ||
| WT | 61 (8.9%) | 185 (27%) | |
| Mut | 284 (41.4%) | 156 (22.7%) | |
| 1p/19q codeletion, n (%) | <0.001 | ||
| Codel | 133 (19.3%) | 38 (5.5%) | |
| Non-codel | 215 (31.2%) | 303 (44%) | |
| Primary therapy outcome, n (%) | 0.004 | ||
| PD | 55 (11.9%) | 57 (12.3%) | |
| SD | 100 (21.6%) | 47 (10.2%) | |
| PR | 42 (9.1%) | 22 (4.8%) | |
| CR | 96 (20.8%) | 43 (9.3%) | |
| Gender, n (%) | 0.146 | ||
| Female | 139 (20%) | 159 (22.8%) | |
| Male | 209 (30%) | 189 (27.2%) | |
| Race, n (%) | 0.383 | ||
| Asian | 4 (0.6%) | 9 (1.3%) | |
| Black or African American | 16 (2.3%) | 17 (2.5%) | |
| White | 319 (46.7%) | 318 (46.6%) | |
| Age, n (%) | <0.001 | ||
| ≤60 | 305 (43.8%) | 248 (35.6%) | |
| >60 | 43 (6.2%) | 100 (14.4%) | |
| Histological type, n (%) | <0.001 | ||
| Astrocytoma | 110 (15.8%) | 85 (12.2%) | |
| Glioblastoma | 17 (2.4%) | 151 (21.7%) | |
| Oligoastrocytoma | 81 (11.6%) | 53 (7.6%) | |
| Oligodendroglioma | 140 (20.1%) | 59 (8.5%) | |
| Age, median (IQR) | 40 (32, 53) | 51 (38, 62) | <0.001 |